BOPA Fellowship Nominations are NOW OPEN!
We are pleased to announce that BOPA Fellowship Nominations have now opened for 2025. There is a clear nomination and selection process including specific criteria for assessing the nominated individuals.…
We are pleased to announce that BOPA Fellowship Nominations have now opened for 2025. There is a clear nomination and selection process including specific criteria for assessing the nominated individuals.…
The 28th British Oncology Pharmacy Association (BOPA) Annual Conference, 3-5 October 2025, ICC Belfast The Draft Agenda is available to view here: https://www.bopa.org.uk/resources/the-28th-bopa-annual-conference-2025-draft-agenda/ The conference will include an exciting variety…
Dear Members, The BOPA research committee would like to invite members to participate in a research project on Genetic core competencies for clinical pharmacists in the cancer setting: a literature…
Overview – This study day is intended to provide an overview of the knowledge, skills, experiences and behaviours required to practice at an advanced level in Cancer Care. The study day…
Vacancy: BOPA Let’s Communicate Cancer Lead Closing Date: 8/6/25 Are you a passionate pharmacy professional with a strong interest in education and training? Do you have the experience and leadership…
Dear BOPA members, The Education and Training subcommittee are pleased to announce that our new e-learning module for myeloma is now live on the BOPA website. The module can…
Dear BOPA member, Tarini Deleep and Dr Pinkie Chambers from University College London are developing a risk prediction model to help identify patients with incurable Non Small Cell Lung Cancer,…
Earlier this year the BOPA Immunotherapy Group wrote, and published, four monographs to help health care professionals care for patients with immune-related adverse events. As a group we are pleased…
The Spring webinar for Women for Oncology UK is on the 16th May, to sign up click the link below. Women For Oncology UK Spring Webinar Tickets, Wed 14 May…
BOPA have been involved with the following NICE TA: Ribociclib with an aromatase inhibitor can be used as an option for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer…
Dear all, In the coming months, an increasing number of products traditionally administered intravenously are expected to become available for subcutaneous administration. This shift offers enhanced flexibility for patients; however,…
We are delighted to share that so many of our members have had manuscripts published recently. Here are some that we are aware of but if there are others then…